Crossmark

EVOLVE-IBERIA: Real-world evidence on vedolizumab and anti-tumor necrosis factor-α as first- or second-line biologic treatment among patients with ulcerative colitis

Crossref DOI link: https://doi.org/10.1016/j.gastrohep.2025.502528

Published Print: 2026-01

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Casellas, Francesc

Gutiérrez-Casbas, Ana

Rodríguez, Cristina

P. Gisbert, Javier

Riestra, Sabino

Herrera de Guise, Claudia

Vera-Mendoza, Isabel

Martínez-Montiel, Pilar

Bernardo, Sónia

Medeiros, Isabel

Aparicio, Jesús

Tagarro, Ignacio

Letosa-Abián, Teresa

Montoto, Carmen

Muñoz, Fernando
License Information

Text and Data Mining valid from 2026-01-01

Text and Data Mining valid from 2026-01-01

Version of Record valid from 2025-07-15
More Information

This article is maintained by: Elsevier

Article Title: EVOLVE-IBERIA: Real-world evidence on vedolizumab and anti-tumor necrosis factor-α as first- or second-line biologic treatment among patients with ulcerative colitis

Journal Title: Gastroenterología y Hepatología

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.gastrohep.2025.502528

Content Type: article

Copyright: © 2025 The Authors. Published by Elsevier España, S.L.U.

Document is current

Any future updates will be listed below